




The relative strengths and weaknesses of Epirus Biopharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Epirus Biopharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 117% points. The greatest weakness of Epirus Biopharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 306%, being 72% points above the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	51,207
Cost of Goods Sold	0
Intangible Assets	21,546
Liabilities, Current	15,544
Liabilities, Non-Current	0
Other Assets	1,872
Other Compr. Net Income	0
Other Expenses	4,689
Other Liabilities	0
Other Net Income	156
Other Revenues	8,184
Property and Equipment	5,258
Research and Development	35,294
Selling, General and Administrative Expense	10,400

Output Variable	Value in 1000 USD
Assets	79,883
Liabilities	15,544
Expenses	50,383
Revenues	8,184
Stockholders Equity	64,339
Net Income	-42,043
Comprehensive Net Income	-42,043
BaseVar	77,075
ECR before LimitedLiability	206%
Economic Capital Ratio	306%